ASH 2019 | D-Kd for RRMM: MMY1001 final analysis
Sagar Lonial
• 8 Dec 2019
Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, discusses the final analysis of a phase 1b MMY1001 study of daratumumab in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma, one arm of the study’s evaluation of daratumumab (D-Kd) in combination with various backbone therapies (NCT01998971). Prof. Lonial highlights how this study lead into the CANDOR trial (NCT03158688), which was part of a late-breaking abstract at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
